Page header

Position of the Transparency Council – Raxone (idebenone)

At its meeting on 19 May 2025, the Transparency Council adopted position No. 63/2025 on the appropriateness of granting approval for reimbursement of the medicinal product Raxone (idebenone) for the indication of Leber’s hereditary optic neuropathy in the pediatric population.

 

Publication of the position >>